Clinical trials: Bone Tumour
Bone Marrow Transplant Complications, Acute Myeloid Leukemia
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
This is an open label Phase I-II study to determine the safe doses of bortezomib, sitagliptin, and PTCy (Phase I) with expansion into a phase II trial to determine efficacy in improving survival.
- Conditions
- Bone Marrow Transplant Complications, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult, Myelodysplastic Syndromes
- Trial name
- NCT05895201
- Testing
- Sitagliptin, Bortezomib, Cyclophosphamide
- Where
- United States
- Sponsor
- Indiana University
Myeloid Leukemia, Chronic
Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response
Imatinib mesylate is standard treatment of Chronic myeloid leukaemia, complete cytogenetic response is obtained in most of cases but molecular response concerned only a small part of the patients.
- Trial name
- AFR22 (NCT00210119)
- Testing
- Glivec
- Where
- 7 sites in France
- Volunteers
- 19 people
- Sponsor
- Institut Bergonié
Myelodysplastic Syndrome
An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome
The purpose of this study is to evaluate the effectiveness and safety of decitabine in the treatment of myelodysplastic syndrome (name of a group of conditions that occur when the blood-forming cells in the bone marrow are…
- Trial name
- NCT01751867
- Testing
- Decitabine at 15 mg/m2, Decitabine at 20 mg/m2
- Where
- 8 sites in China
- Volunteers
- 135 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment.
- Trial name
- NCT05201066
- Testing
- decitabine, spartalizumab, sabatolimab
- Where
- 24 sites in United States, Australia and 13 more
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Myelofibrosis，MF
Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia
We hypothesize that pacritinib leads to modification of the myelofibrosis (MF) disease phenotype, especially related to BM fibrosis and cytopenias; due potentially to its dual effect as an inhibitor of the JAK and NFκB pathways…
- Trial name
- PACRIMYEL (NCT07394153)
- Testing
- Pacritinib
- Where
- 13 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas
Basal Cell Nevus Syndrome
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
This is a multicenter, open label extension study evaluating the safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult subjects with Gorlin syndrome.
- Trial name
- NCT04308395
- Testing
- Patidegib Topical Gel, 2%
- Where
- 37 sites in United States, Belgium and 7 more
- Volunteers
- 108 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Bone Marrow Transplant Complications, Graft-versus-Host Disease
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
The goal of this study is to demonstrate the efficacy of a multidisciplinary group-based telehealth intervention (HORIZONS) compared to minimally enhanced usual care for improving self-management and quality of life for…
- Trial name
- HORIZONS (NCT06910969)
- Testing
- HORIZONS Intervention, Minimally enhanced usual care
- Where
- 2 sites in United States
- Volunteers
- 350 people
- Sponsor
- Massachusetts General Hospital
Leukemia, Myelogenous, Acute, Myelodysplastic Syndromes
A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS
This study is intended to determine the safety and maximum tolerated dose of a drug, OXi4503 (combretastatin A1 diphosphate, CA1P, OXiGENE), in patients with relapsed and refractory AML and MDS.
- Trial name
- NCT01085656
- Testing
- OXi4503
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Florida
Leukemia, Myelodysplastic Syndromes
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as azacitidine and arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00118196
- Testing
- arsenic trioxide, azacitidine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Medical University of South Carolina
Graft vs Host Disease, Multiple Myeloma
Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation
Both patients and marrow donors are treated on Regimen A; patients then proceed to Regimen B. The following acronyms are used: ABM Allogeneic Bone Marrow BU Busulfan, NSC-750 CF Leucovorin calcium, NSC-3590 CTX Cyclophosphamide…
- Trial name
- NCT00001561
- Testing
- Myeloma Immunoglobulin Idiotype Vaccine-KLH, GM-CSF
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00334854
- Testing
- doxorubicin hydrochloride, ifosfamide, adjuvant therapy
- Where
- 28 sites in Austria, Belgium and 7 more
- Volunteers
- 250 people
- Sponsor
- European Paediatric Soft Tissue Sarcoma Study Group
Hematologic Malignancies, Inherited Disorders of Metabolism
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
- Conditions
- Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders
- Trial name
- NCT01351545
- Testing
- A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
- Where
- 142 sites in United States
- Volunteers
- 99,999 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Leukemia
Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment
RATIONALE: Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood and may bring about complete remission in patients who have chronic phase chronic…
- Trial name
- NCT00072579
- Testing
- sargramostim
- Where
- 15 sites in United States
- Sponsor
- Wake Forest University Health Sciences
Chronic Myeloid Leukemia
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients.
- Trial name
- ENESTop (NCT01698905)
- Testing
- nilotinib
- Where
- 62 sites in United States, Argentina and 16 more
- Volunteers
- 163 people
- Sponsor
- Novartis Pharmaceuticals
Spinal Cord Neoplasms, Spinal Neoplasms
Intradurale Spinal Tumors: Management and Treatment
Intradurale spinal tumors are rare neoplastic lesions that involve the spinal cord and surrounding structures and may cause neurological symptoms such as pain, motor deficits, sensory disturbances, and sphincter dysfunction.
- Trial name
- GTTIR (NCT07488702)
- Testing
- Surgical Resection of Intradural Spinal Tumors
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Breast Cancer, Colorectal Cancer
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of solid tumors by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00620295
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Myelofibrosis
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
The study is a designed to evaluate safety and activity of APG-1252 when administered as monotherapy and in combination with ruxolitinib in previously ruxolitinib treated myelofibrosis patients.
- Trial name
- NCT04354727
- Testing
- APG-1252, Ruxolitinib
- Where
- 2 sites in United States
- Sponsor
- Ascentage Pharma Group Inc.
Progression, Survival
PD-L1 Expression in Advanced Osteosarcoma
The expression level of PD-L1 on tumor cells is a pivotal point which might have some influence on prognosis, especially for those who might use PD-1 or PD-L1 antibody for treatment.
- Trial name
- NCT03582527
- Testing
- all study participants
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Myeloid Malignancy, Acute Myeloid Leukemia
A Telehealth Advance Care Planning Intervention
The objective of this project is to conduct a pilot randomized trial to assess the preliminary efficacy of a telehealth-delivered Serious Illness Care Program on healthcare communication, patient anxiety and distress, as well as…
- Conditions
- Myeloid Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- SICP RCT (NCT05875805)
- Testing
- Telehealth Serious Illness Care Program, Education Control
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- University of Rochester
Chronic Myeloid Leukemia in Chronic Phase
Managed Access Programs for ABL001, Asciminib
The purpose of this registration form is to list all Managed Access Programs (MAPs) related to ABL001, asciminib
- Trial name
- NCT04360005
- Testing
- Asciminib
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.